Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cardiac ion channels, most notably the human Ether-à-go-go-Related Gene (hERG) potassium channel, are specialized transmembrane proteins that orchestrate the electrical activity of the heart by regulating the flow of ions such as potassium, sodium, and calcium (UniProt P51787). The hERG channel (Kv11.1) is responsible for the rapid delayed rectifier potassium current (IKr), which is the primary driver of ventricular repolarization (PubMed 11114339). Other critical channels include the SCN5A-encoded sodium channel (Nav1.5) and the CACNA1C-encoded L-type calcium channel (Cav1.2), which facilitate depolarization and the action potential plateau, respectively (UniProt P35498, Q13936). While these channels are therapeutic targets for antiarrhythmic medications, they are also significant "antitargets" in drug development because unintended inhibition—particularly of hERG—can lead to delayed repolarization and QT interval prolongation (ICH S7B). This delay increases the risk of life-threatening arrhythmias, such as Torsades de Pointes, making cardiac ion channel screening a cornerstone of preclinical safety pharmacology (PubMed 12756208).
Drugs typically act as pore blockers or allosteric modulators that inhibit or enhance the flow of ions (K+, Na+, or Ca2+) across the cardiac cell membrane, thereby altering the duration and shape of the action potential.
9 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Potassium voltage-gated channel subfamily H member 2 (hERG) and other cardiac ion channels (hERG and CICs).